Sharon Arnold, APRN
Primary Care · Batesville, ARNPI 1306409271
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.7% of the total across 137 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $748 and has fallen 96.9% since, to $23 in 2025.
Across 137 payments — averaging $16.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$381
- AstraZeneca$169
- Boehringer Ingelheim$149
- Sunovion Pharmaceuticals Inc.$145
- Bayer$135
- GSK$122
- plus $1K from 19 others
What the payments were for
- Food & beverage$2,19696%
- Education$994%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 20 | $381 |
| AstraZeneca | 11 | $169 |
| Boehringer Ingelheim | 9 | $149 |
| Sunovion Pharmaceuticals Inc. | 9 | $145 |
| Bayer | 8 | $135 |
| GSK | 8 | $122 |
| Sumitomo Pharma America, Inc. | 8 | $121 |
| AbbVie | 6 | $120 |
| Otsuka America Pharmaceutical, Inc. | 6 | $107 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $104 |
| Novo Nordisk | 6 | $93 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $90 |
| Amgen | 5 | $89 |
| Lilly USA, LLC | 5 | $69 |
| Merck | 5 | $68 |
| Lundbeck LLC | 4 | $66 |
| Grifols USA, LLC | 3 | $50 |
| Idorsia Pharmaceuticals US Inc | 3 | $46 |
| Mylan Specialty L.p. | 2 | $35 |
| Axsome Therapeutics, Inc. | 1 | $30 |
| Novartis | 2 | $28 |
| Ironwood Pharmaceuticals, Inc | 2 | $24 |
| Insmed, Inc. | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Exact Sciences | 1 | $14 |
How this compares
$2,295 in reported general payments places this provider in the 85th percentile of 76 primary care providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 83 | $73,073 |
| MounjaroTirzepatide | 41 | $47,212 |
| Abilify MaintenaAripiprazole | 14 | $38,293 |
| FarxigaDapagliflozin Propanediol | 45 | $32,735 |
| OzempicSemaglutide | 28 | $26,542 |
| TrulicityDulaglutide | 29 | $25,910 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $18,495 |
| EliquisApixaban | 14 | $16,255 |
| KerendiaFinerenone | 11 | $15,870 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 14 | $10,755 |
| Aimovig AutoinjectorErenumab-Aooe | 12 | $7,707 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 14 | $7,169 |
| MyrbetriqMirabegron | 12 | $7,132 |
| BelsomraSuvorexant | 16 | $7,070 |
| MovantikNaloxegol Oxalate | 11 | $6,137 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Stiolto Respimat | $149 | $83,82897 claims |
| Lilly USA, LLCMounjaro, Trulicity | $69 | $73,12270 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $107 | $38,29314 claims |
| AstraZenecaFarxiga, Symbicort | $169 | $37,18564 claims |
| Novo NordiskOzempic | $93 | $26,54228 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $122 | $25,66442 claims |
| BayerKerendia | $135 | $15,87011 claims |
| Astellas Pharma US IncMyrbetriq | $381 | $7,13212 claims |
| MerckBelsomra | $68 | $7,07016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 76 primary care providers in Arkansas.
Other primary care in Batesville
- Andrew OliverMaumelle$45K
- Chelsea PressonLittle Rock$22K
- Stephen RohrerWynne$15K
- Chelsea MarquisSpringdale$12K
- Katherine ThompsonLittle Rock$10K
- Barbara ColeNorth Little Rock$9K
- Celeste WilliamsCenterton$6K
- Jennifer RogersCharleston$4K
- Meghan SkinnerSearcy$4K
- Krystalyn WilliamsLittle Rock$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.